{
  "docId": "019de076-7e9d-767a-a7eb-99a77c1645c5",
  "docSlug": "225408061c3ed04b028031d27cf2467f",
  "documentTitle": "Immix Biopharma | Investor Presentation Deck | 62 slides",
  "authorId": "immix-biopharma",
  "authorName": "ImmixBio",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-12-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 23,
  "pageCount": 62,
  "prevPage": 22,
  "nextPage": 24,
  "slideType": "competitive_analysis",
  "function": "compare_peers",
  "density": "balanced",
  "nDataPoints": 4,
  "notes": "The slide explicitly notes that these are cross-trial comparisons and not head-to-head results.",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de076-7e9d-767a-a7eb-99a77c1645c5/23",
  "deckHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5",
  "deckJsonHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5.json",
  "deckAnchorHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5#slide-23",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.23,
        "x": 0.32,
        "y": 0.375
      },
      "kind": "callout",
      "text": "NXC-201 67% improvement in response rates",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e7724914-c8d7-4616-8f11-aa351cbed03a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.7,
        "w": 0.6,
        "x": 0.2,
        "y": 0.2
      },
      "kind": "chart",
      "text": "Complete Response Rates in BCMA-exposed multiple myeloma",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "eb7fc79a-e741-493b-92d0-0f8eab676b4a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.95,
        "x": 0.02,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Source: 49th EBMT (NXC-201) presentation, Elrexfio FDA approval label, Cohen et al 2023. Note: Elrexfio reflects overall response rate (complete response rate not reported on FDA label). Figures reflect cross-trial comparison.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0cb1e3bc-cba9-4651-9cb0-1ead53a251c2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.45,
        "x": 0.02,
        "y": 0.04
      },
      "kind": "title",
      "text": "Only CAR-T in BCMA-exposed multiple myeloma, a rapidly growing patient segment (2/2)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cbb2e719-953b-459b-b930-7307e3384a13",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Chart Selection Guide",
      "slug": "chart-selection-guide",
      "agent": "Designer",
      "layer": "slide",
      "matchId": "5c370404-cb41-4f93-b745-1bbe6fcd6c5a",
      "evidence": "Chart/bar-vertical: Complete Response Rates in BCMA-exposed multiple myeloma",
      "confidence": 0.6
    }
  ],
  "frameworks": [
    {
      "name": "comparison_frame",
      "slug": null,
      "matchId": "daf966fd-821e-40a7-bc89-f905d95fe4cf",
      "evidence": "Direct visual comparison of performance metrics between proprietary product and competitors.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 34,
      "from": 15,
      "beatId": "167b9d6c-4f69-438b-b991-0f1839680299",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Evidence & Proof",
      "beatSlug": "consultants-gambit-evidence-proof",
      "evidence": "The document presents clinical data and evidence supporting the safety and efficacy of NXC-201.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [
    {
      "to": 30,
      "from": 20,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "c5885b1a-6ad4-4bdc-aca6-7fa2b459dcc5",
      "evidence": "The document presents the market opportunity and potential for NXC-201 to disrupt the oncology and immunology categories.",
      "position": 0,
      "objective": "What is the cost of not adopting NXC-201, and how does it compare to existing therapies?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    },
    {
      "to": 33,
      "from": 21,
      "name": "David Goliath",
      "slug": "16-david-goliath",
      "bestFor": "Startups, disruptive innovation, competitive displacement",
      "matchId": "9ea06d5c-25e8-4720-a131-3da94cd15b18",
      "evidence": "The document presents clinical data and comparisons to existing therapies.",
      "position": 1,
      "objective": "How does NXC-201 compare to existing therapies in terms of efficacy and safety?",
      "structure": "The Giant's Weakness -> Our Slingshot (Unique Edge) -> The Topple",
      "confidence": 0.7,
      "description": "Frame your initiative as the nimble underdog taking on a slow, bloated incumbent"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}